Urinary excretion of Bowman-Birk inhibitor in humans after soy consumptionas determined by a monoclonal antibody-based immunoassay

Citation
Xs. Wan et al., Urinary excretion of Bowman-Birk inhibitor in humans after soy consumptionas determined by a monoclonal antibody-based immunoassay, CANC EPID B, 9(7), 2000, pp. 741-747
Citations number
23
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
ISSN journal
10559965 → ACNP
Volume
9
Issue
7
Year of publication
2000
Pages
741 - 747
Database
ISI
SICI code
1055-9965(200007)9:7<741:UEOBII>2.0.ZU;2-X
Abstract
The Bowman-Birk inhibitor (BBI) found in soybeans is a serine protease inhi bitor with anticarcinogenic activity. In the present study, an ELISA for BB I mas developed with the use of a monoclonal antibody against a reduced for m of BBI, This newly developed ELISA method was used to measure the urinary levels of BBI metabolites in nine human subjects after consumption of 36-o z or 60-oz soymilk (containing 105 or 175 mg of BBI) at two time points 36 h apart. The results demonstrate that urinary BBI excretion rates peaked wi thin 6 h and decreased to baseline levels within 12-24 h after soymilk inge stion. The changes in BBI:creatinine ratios in urine closely paralleled the changes in urinary BBI excretion rates after soymilk consumption. These da ta suggest that BBI ingested p.o. is absorbed and could be bioavailable for cancer chemoprevention in other organs in addition to those in the gastroi ntestinal tract.